EP Patent

EP1927354A1 — Novel substituted benzimidazole dosage forms and method of using same

Assigned to University of Missouri Columbia · Expires 2008-06-04 · 18y expired

What this patent protects

A solid oral pharmaceutical composition, comprising: a) a proton pump inhibitor; and b) at least one buffering agent; wherein said composition is in a dosage form selected from the group consisting of a powder, a tablet, a suspension tablet, a chewable tablet, a capsule, an …

USPTO Abstract

A solid oral pharmaceutical composition, comprising: a) a proton pump inhibitor; and b) at least one buffering agent; wherein said composition is in a dosage form selected from the group consisting of a powder, a tablet, a suspension tablet, a chewable tablet, a capsule, an effervescent powder, an effervescent tablet, pellets and granules, and wherein said dosage form is not enteric coated or time-released

Drugs covered by this patent

Patent Metadata

Patent number
EP1927354A1
Jurisdiction
EP
Classification
—
Expires
2008-06-04
Drug substance claim
No
Drug product claim
No
Assignee
University of Missouri Columbia
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.